A1M Pharma AB:製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:A1M Pharma AB - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C11215
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:30
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:スウェーデン
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
A1M Pharma AB (A1M Pharma) is a developer of a medical application for the diagnosis and treatment of pre-eclampsia and acute renal damage. The company develops and commercializes drug candidate for the diagnosis and treatment of pre-eclampsia (pandemic poisoning) and acute renal injury. It offers products such as ROSgard based on A1M (alpha-1-microglobulin), an endogenous protein with properties that captures and eliminates toxic substances from the cells metabolism. A1M Pharma’s A1M helps to prevent and ameliorate some of the damage caused by oxidative stress and inflammation; and develops novel diagnostic test for preeclampsia based on the biomarker fetal hemoglobin. The company also develops treatments for kidney damage. It also provides constitute therapeutic or diagnostic tools for various conditions and illnesses in animals and humans. A1M Pharma is headquartered in Lund, Sweden.

A1M Pharma AB – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
A1M Pharma AB, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
A1M Pharma AB, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
A1M Pharma AB, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
A1M Pharma AB, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
A1M Pharma AB, Medical Devices Deals, 2012 to YTD 2018 9
A1M Pharma AB, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
A1M Pharma AB, Pharmaceuticals & Healthcare, Deal Details 11
Partnerships 11
A1M Pharma Partnered with Clinical Trial Consultants 11
A1M Pharma Enters into Agreement with Research Toxicology Centre 12
A1M Pharma Enters into Research Agreement with CSL Behring 13
A1M Pharma Enters into Rresearch Agreement with Fred Hutchinson Cancer Research Centre 14
A1M Pharma Expands Agreement with European Pharmaceutical Company 15
A1M Pharma Enters into Partnership with Truly Translational 16
NeuroVive Pharmal And A1M Pharma Enter Into Research Agreement 17
Equity Offering 18
A1M Pharma Plans to Raise USD10.5 Million in Rights Offering of Shares 18
A1M Pharma Plans to Raise USD13.82 Million in Public Offering of Shares 19
A1M Pharma Raises USD5 Million in Rights Offering of Shares 20
A1M Pharma Raises USD3.7 Million in Rights Offering of Shares 21
A1M Pharma Raises USD3.61 Million in Rights Offering of Shares 22
A1M Pharma AB – Key Competitors 23
A1M Pharma AB – Key Employees 24
A1M Pharma AB – Locations And Subsidiaries 25
Head Office 25
Other Locations & Subsidiaries 25
Recent Developments 26
Corporate Communications 26
Aug 14, 2018: A1M Pharma names Tobias Larsson Agervald as Chief Medical Officer 26
Product News 27
02/10/2017: A1M Pharma has successfully conducted large scale manufacturing of the active substance in ROSGard and initiates GLP toxicology studies 27
Clinical Trials 28
Jun 12, 2017: A1M Pharma announces progress in the preclinical development of ROSGard 28
Mar 29, 2017: A1M Pharma: ROSGard shows strong protective effect against renal damage in connection with radiation therapy in a preclinical long-term study 29
Appendix 30
Methodology 30
About GlobalData 30
Contact Us 30
Disclaimer 30

List of Tables
A1M Pharma AB, Pharmaceuticals & Healthcare, Key Facts 2
A1M Pharma AB, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
A1M Pharma AB, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
A1M Pharma AB, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
A1M Pharma AB, Deals By Therapy Area, 2012 to YTD 2018 8
A1M Pharma AB, Medical Devices Deals, 2012 to YTD 2018 9
A1M Pharma AB, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
A1M Pharma Partnered with Clinical Trial Consultants 11
A1M Pharma Enters into Agreement with Research Toxicology Centre 12
A1M Pharma Enters into Research Agreement with CSL Behring 13
A1M Pharma Enters into Rresearch Agreement with Fred Hutchinson Cancer Research Centre 14
A1M Pharma Expands Agreement with European Pharmaceutical Company 15
A1M Pharma Enters into Partnership with Truly Translational 16
NeuroVive Pharmal And A1M Pharma Enter Into Research Agreement 17
A1M Pharma Plans to Raise USD10.5 Million in Rights Offering of Shares 18
A1M Pharma Plans to Raise USD13.82 Million in Public Offering of Shares 19
A1M Pharma Raises USD5 Million in Rights Offering of Shares 20
A1M Pharma Raises USD3.7 Million in Rights Offering of Shares 21
A1M Pharma Raises USD3.61 Million in Rights Offering of Shares 22
A1M Pharma AB, Key Competitors 23
A1M Pharma AB, Key Employees 24
A1M Pharma AB, Subsidiaries 25

List of Figures
A1M Pharma AB, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
A1M Pharma AB, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
A1M Pharma AB, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
A1M Pharma AB, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
A1M Pharma AB, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
A1M Pharma AB, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
A1M Pharma AB, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
A1M Pharma AB, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
A1M Pharma AB, Medical Devices Deals, 2012 to YTD 2018 9

★海外企業調査レポート[A1M Pharma AB:製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Bio-Rad Laboratories Inc (BIO):企業の財務・戦略的SWOT分析
    Bio-Rad Laboratories Inc (BIO) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakn …
  • Zen Technologies Limited:企業の戦略・SWOT・財務分析
    Zen Technologies Limited - Strategy, SWOT and Corporate Finance Report Summary Zen Technologies Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service o …
  • Vinci SA:企業のM&A・事業提携・投資動向
    Vinci SA - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Vinci SA Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, capital …
  • Temple University-製薬・医療分野:企業M&A・提携分析
    Summary Temple University (Temple) is an educational and research university that offers undergraduate and graduate courses. The university offers undergraduate courses in various fields which include arts, media and communication, medicine, engineering, pharmacy and others. Temple offers its degree …
  • UPL Ltd (UPL):企業の財務・戦略的SWOT分析
    UPL Ltd (UPL) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the pot …
  • Purplebricks Group plc:企業の戦略・SWOT・財務分析
    Purplebricks Group plc - Strategy, SWOT and Corporate Finance Report Summary Purplebricks Group plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offer …
  • China International Water & Electric Corp:企業の戦略的SWOT分析
    China International Water & Electric Corp - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and …
  • DiaSorin SpA (DIA):企業の財務・戦略的SWOT分析
    DiaSorin SpA (DIA) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and th …
  • Medtronic Plc (MDT):医療機器:M&Aディール及び事業提携情報
    Summary Medtronic Plc (Medtronic), formerly Medtronic Inc, is a medical technology company that designs, develops, manufactures and markets a wide range of medical devices and solutions for the treatment of heart failure; heart valve disorders; diseases of the coronary artery; aortic; peripheral vas …
  • Proxy Biomedical Ltd-医療機器分野:企業M&A・提携分析
    Summary Proxy Biomedical Ltd (PBL) is a medical device company that research, develops and manufactures biomaterials for medical implant products. The company’s products include composite mesh, flat sheet 2D and 3D mesh, hernia plugs, resorbable synthetic mesh, resorbable surgical mesh, specialty su …
  • QIC Ltd:企業の戦略・SWOT・財務情報
    QIC Ltd - Strategy, SWOT and Corporate Finance Report Summary QIC Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, pr …
  • Seylan Bank Plc
    Seylan Bank Plc - Strategy, SWOT and Corporate Finance Report Summary Seylan Bank Plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpo …
  • Websol Energy System Ltd (WEBELSOLAR):企業の財務・戦略的SWOT分析
    Summary Websol Energy System Ltd (Websol) is an alternate energy company that offers manufacturing of photovoltaic crystalline solar cells and the related modules. The company offers products such as pv solar cell and pv solar module. Its pv solar cell includes multi crystalline 4bb pv solar cell, m …
  • Mobile Tornado Group Plc (MBT):企業の財務・戦略的SWOT分析
    Summary Mobile Tornado Group Plc (Mobile Tornado) is a technology company that offers communication services. The company offers solutions such as instant messaging solutions, voice communication, one-to-one and one-to-many; and instant alert that enables workforce to raise alerts in a range of situ …
  • Microbix Biosystems Inc (MBX):企業の財務・戦略的SWOT分析
    Summary Microbix Biosystems Inc (Microbix) provides biological and technology solutions for human health and wellbeing. The company's products include infectious disease antigens and quality assessment products. It manufactures viral and bacterial antigens and reagents for the diagnostics. Microbix …
  • Impinj Inc (PI):企業の財務・戦略的SWOT分析
    Impinj Inc (PI) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the p …
  • Thales SA:企業のM&A・事業提携・投資動向
    Thales SA - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Thales SA Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, capita …
  • Bonheur ASA (BON):石油・ガス:M&Aディール及び事業提携情報
    Summary Bonheur ASA (Bonheur) is an oil and gas investment service provider that offers investment services for various energy sectors. The company invests in renewable energy, cruise, shipping and offshore wind, offshore drilling, and other investments. It operates shipping vessels for transport an …
  • Mirvac Group:企業の戦略・SWOT・財務情報
    Mirvac Group - Strategy, SWOT and Corporate Finance Report Summary Mirvac Group - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate a …
  • The Pep BoysManny, Moe & Jack:企業の戦略・SWOT・財務情報
    The Pep BoysManny, Moe & Jack - Strategy, SWOT and Corporate Finance Report Summary The Pep BoysManny, Moe & Jack - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆